

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification ⁶ :		(11) International publication number:	WO 98/48836
A61K 39/106	A1	(43) International publication date:	5 November 1998 (05.11.98)
(21) International application number:	PCT/FR98/00875	(81) Designated states:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO Patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International filing date:	30 April 1998 (30.04.98)	(30) Data relating to the priority:	
(71) Applicant (for all designated States except US): MERIEUX ORAVAX [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR).	97/05,608 30 April 1997 (30.04.97) 97/15,732 8 December 1997 (08.12.97)	(72) Inventors; and	
(73) Inventors/Applicants (US only): Bruno GUY [FR/FR]; 15B, rue des Noyer, F-69005 Lyon (FR). Jean HAENSLER [FR/FR]; "Les Bullandières" Bâtiment B, 17, rue Piccadet, F-69290 Saint Genis les Ollières (FR).	FR	(74) Representative:	Marie-Pauline AYROLES; Pasteur Mérieux Séums & Vaccins, Industrial Property Directorate, 58, avenue Leclerc, F-69007 Lyon (FR).

As printed

(54) Title: ANTI-*HELICOBACTER* VACCINE COMPOSITION COMPRISING A TH1 ADJUVANT(54) Titre: COMPOSITION VACCINALE ANTI-*HELICOBACTER* COMPRENANT UN ADJUVANT DE TYPE TH1

(57) Abstract

The invention concerns the use of an immunogenic agent derived from *Helicobacter*, associated with an adjuvant such as QS-21, DC-chol or Bay R1005, for making a pharmaceutical composition designed to induce an immune response of the T helper 1 type (Th1), for preventing or treating *Helicobacter* infection in a mammal.

(57) Abrégé

L'invention a pour objet l'usage d'un agent immunogène dérivé d'*Helicobacter*, en association avec un adjuvant tel que le QS-21, le DC-chol ou le Bay R1005, dans la fabrication d'une composition pharmaceutique destinée à l'induction d'une réponse immunitaire de type T helper 1 (Th1) à l'encontre d'*Helicobacter*, pour prévenir ou traiter une infection à *Helicobacter* chez un mammifère.